Efficacy of pembrolizumab in urothelial cancer: A systematic review and meta-analysis
Bladder · 2025
DOI: 10.14440/bladder.0249 ↗Abstrakt
Background: Urothelial bladder cancer is a major health challenge owing to its high incidence, elevated mortality rates, and clinical diversity. Objective: This systematic review and meta-analysis assesses the efficacy of pembrolizumab in the treatment of non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic urothelial carcinoma (mUC). After applying the inclusion and exclusion criteria, a literature search of PubMed, Scopus, and Web of Science (January 2020–June 2025) identified eight studies on NMIBC, MIBC, and mUC for the final analysis. Analysis revealed an advantage of pembrolizumab-based treatment (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.70–2.03). Subgroup analyses showed the effectiveness in MIBC (OR: 1.88; 95% CI: 1.65–2.12) and mUC (OR: 1.94; 95% CI: 1.82–2.11). In contrast, the NMIBC subgroup lacked significance (OR: 1.28; 95% CI: 0.86–1.91), reflecting the evidence from small, early-phase studies. Pembrolizumab showed improved pathological complete response, progression-free survival, and disease-free survival in groups with elevated programmed death-ligand 1 expression and a high tumor mutational burden. Conclusion: Pembrolizumab is highly effective in treating MIBC and mUC; however, its impact on NMIBC remains uncertain. The limited number of studies and brief follow-up periods highlight the need for larger trials with long-term survival data.
EUVIMED